Background: Several previous clinical trials have shown that malignant pleural mesothelioma is responsive to antifolates. The dihydrofolate reductase inhibitor, pralatrexate, has a favorable toxicity profile, primarily limited to stomatitis, and has demonstrated activity in patients with non-small cell lung cancer. In mesothelioma cell lines and xenografts, pralatrexate demonstrated significant antitumor activity. Methods: We conducted this phase II study to determine the response rate of malignant pleural mesothelioma to pralatrexate at a dose of 135 mg/m 2 IV every 2 weeks. After a protocol amendment, patients were supplemented with vitamin B 12 and folic acid at the time of starting therapy. Results: A total of 16 assessable patients were enrolled. No complete or partial responses were observed. Two patients with epithelioid histology had minor responses. Three other patients remained on study with stable disease for 9, 9, and 48 months. The median time to progression was 3 months. The overall median survival time was 7 months (95% confidence interval: 3.2-16.2 months) and the one-year survival was 31% (95% confidence interval: 15%-65%). Three patients (19%) had grade 2 stomatitis, eight (50%) had grade 3, and one (6%) had grade 4. Conclusions: With this particular dose and schedule, pralatrexate as a single agent had no activity in malignant pleural mesothelioma.
M alignant mesothelioma arising from the parietal pleura afflicts 2000 to 3000 Americans annually. 1 All known treatment modalities, including surgery, radiation, and chemotherapy, have little effect on survival. Chemotherapy, in particular, has historically been inadequate. Phase II studies generally show response rates to chemotherapy of less than 15% and median survival times of 6 to 10 months. 2 As a class, the antifolates stand out as showing somewhat more efficacy than others. [3] [4] [5] [6] [7] In phase III studies, pemetrexed 6 and raltitrexed 5 improved survival when combined with cisplatin. Pemetrexed and cisplatin became the first and only chemotherapy regimen approved by the U.S. Food and Drug Administration for this disease in 2004 .
In this study, we evaluated the efficacy of the antifolate pralatrexate (otherwise known as 10-propargyl-10-deazaaminopterin, or PDX) in patients with mesothelioma. Pralatrexate, an inhibitor of dihydrofolate reductase, has greater affinity for the RFC-1 folate transporter and folylpolyglutamate synthetase than other antifolates. 8 In addition to the superior antitumor activity observed in human breast and lung cancer cell lines and xenografts, pralatrexate shows significant cytotoxicity against mesothelioma. 9, 10 Pralatrexate inhibited the growth of VAMT-1 and JMN mesothelioma cell lines 25 to 30 times better than methotrexate and three times better than edatrexate. In established JMN xenografts in nude mice, pralatrexate induced tumor shrinkage and complete remission, neither of which was observed with methotrexate or edatrexate. The antitumor effects were even greater when pralatrexate was combined with cisplatin or carboplatin. Clinically, pralatrexate exhibited an excellent safety profile in a phase I trial, with a primary toxicity of stomatitis and no significant myelosuppression. 11 Furthermore, antitumor activity was demonstrated in a phase II trial of non-small cell lung cancer. 12 
PATIENTS AND METHODS
Chemotherapy-naive patients with unresectable malignant pleural mesothelioma were eligible. After an amendment, patients who had received one previous chemotherapy regimen (but not with an antifolate) were also eligible. Patients were required to have a Karnofsky performance status of Ն70%. Measurable or evaluable indicator lesions that had not been irradiated were necessary. Laboratory parameters included a white blood cell count Ն4000/l, hemoglobin Ն10 g/dl, platelet count Ն160/l, total bilirubin Յ1.0 mg/dl, aspartate aminotransferase Յ1.5 ϫ upper limits of normal (ULN), alkaline phosphatase Յ5 ϫ ULN, and creatinine Յ1.5 mg/dl or creatinine clearance Ն50 mg/min/1.7 m 2 . Because of the potential for drug accumulation in fluid collections, patients with clinically significant pleural effusions or ascites, grade 3 or 4 edema, or previous pneumonectomy were excluded. Patients with a concurrent active cancer or uncontrolled brain or leptomeningeal disease were also excluded. This protocol was reviewed by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center. All patients signed an informed consent document.
Based on the dose used in the phase II trial in non-small cell lung cancer, patients were treated with pralatrexate at 135 mg/m 2 intravenous push every 2 weeks. Two treatments were defined as one cycle (4 weeks). Patients had a computed tomography scan to evaluate for response after the first cycle and then every two cycles thereafter. Modified Response Evaluation Criteria in Solid Tumors were used to assess response. 13 Toxicities were graded using the National Cancer Institute Common Toxicity Criteria version 2.0. Patients with mucositis on the day of treatment were held for a week until resolution. Patients with grade 3 or higher mucositis at any time were treated on subsequent cycles with a 50% dose reduction.
A Simon two-stage design was employed to calculate sample size. 14 With an unacceptable response rate (p0) of 0.05, a desirable response rate (p1) of 0.20 and with ␣ and ␤ errors of 0.10, the initial cohort of 12 patients would be enrolled, expanded to 37 patients if one or more partial responses were observed.
When this trial opened, there were concerns that vitamin supplementation would lessen the activity of pralatrexate. This was based on two sequential Cancer and Leukemia Group B studies in mesothelioma in which a lower response rate and survival time occurred when leucovorin was added to edatrexate. 3 For this reason, patients were instructed to discontinue any folic acid supplementation, including in multivitamins, for 7 days before starting therapy. Only after patients developed stomatitis would they initiate folic acid supplementation. However, subsequent reports supported the use of vitamin B 12 and folic acid supplementation with pemetrexed, which lessened side effects without diminishing efficacy. 6, 15 Furthermore, in an LX-1 lung cancer xenograft model, folic acid supplementation did not adversely affect tumor response to pralatrexate (F.M. Sirotnak, unpublished data). As a result, this trial was amended (after the first nine patients had been enrolled) to add vitamin supplementation. Patients received folic acid 1 mg orally daily and vitamin B 12 1000 g intramuscularly beginning at least 7 days before starting pralatrexate. Folic acid continued daily and vitamin B 12 was administered every 9 weeks. The trial was expanded so that 12 patients treated with vitamin premedications would be enrolled in the first cohort. Folate levels were measured for all patients at baseline. Homocysteine serum concentrations were measured at baseline and before each cycle. Methylmalonic acid levels were not collected. No complete or partial responses were observed (0% observed rate, 95% confidence interval: 0 -21%). Two patients with epithelioid histology had minor tumor shrinkage that did not meet criteria for response. One of these patients was taken off study due to severe stomatitis, and after re-evaluation, she underwent a complete surgical resection followed by hemithoracic radiation; she remained disease free for 2 years. The second patient continued on study for a total of 31 months. Three other patients remained on study with stable disease for 9, 9, and 48 months. All these patients were in the first cohort, and all but one required dose reduction and vitamin supplementation due to toxicity.
RESULTS

From
The median time to progression was 3 months. The overall median survival was 7 months (95% confidence interval: 3.2-16.2 months). The 1-year survival was 31% (95% confidence interval: 15%-65%). The Kaplan-Meier survival curve is shown in Figure 1 . The sample size is too small to elucidate any difference in survival or other outcome measures between the groups of patients who were or were not supplemented with vitamins.
Toxicities
The primary toxicity of pralatrexate was stomatitis (Table 2) . Three patients (19%) had grade 2 stomatitis, eight (50%) had grade 3, and one (6%) had grade 4. Every patient treated without vitamins developed at least grade 2 stomatitis. Conversely, four of seven patients who received vitamin supplementation had no stomatitis, but the other three had grade 3. One patient developed an ulceration on his penis (grade 3) deemed related to study drug. One patient died of Clostridium difficile colitis shortly after coming off study for disease progression. The mean serum homocysteine concentrations did not differ for patients with stomatitis (11.85 M/l, n ϭ 4) or without stomatitis (11.5 M/l, n ϭ 11). Because some patients had serum folate concentrations and others had red blood cell folate concentrations at baseline, no conclusion could be drawn about the correlation of these and stomatitis.
DISCUSSION
This phase II trial evaluated the activity and toxicity of the antifolate pralatrexate in patients with malignant pleural mesothelioma. No responses were observed, although several patients were on treatment for an extended period of time, including two patients treated for 31 and 48 months.
The activity of pralatrexate as a single agent at this dose and schedule appears to be less than that observed with pemetrexed which had a 14% response rate in a phase II single-agent trial. 16 One explanation may be that inhibition of other enzymes involved with folate metabolism accounts for the greater activity of pemetrexed. Pemetrexed primarily inhibits thymidylate synthase but also inhibits dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. 17 However, raltitrexed, which selectively inhibits thymidylate synthase, has also been shown to improve survival for patients with mesothelioma when given in combination with cisplatin. 5 Other factors need to be considered. First, this study with pralatrexate included a challenging cohort of patients, with three octogenarians (19%) and five patients (31%) with nonepithelioid histology. Second, a high rate of toxicity may have affected drug delivery of pralatrexate. Every patient treated without previous vitamin B 12 and folic acid had at least grade 2 stomatitis, and dose reductions were necessary for the patients who stayed on study after the first cycle. Of the patients managed with vitamin supplementation from the outset, four of seven had no stomatitis, although it was severe (grade 3) in the patients who did experience it. As a comparison, in the previous phase II trial All patients (n ϭ 16) Alopecia 6 (38%) 1 (6%) N/A N/A Anemia 0 (0%) 0 (0%) 1 (6%) 0 (0%) Dry eyes 2 (13%) 0 (0%) 0 (0%) 0 (0%)
in non-small cell lung cancer, half of the patients treated without vitamin supplementation at the same dose and schedule had no stomatitis. 12 Pralatrexate administered at other doses or schedules may yield more favorable results, and these are being explored. In the original phase I study of pralatrexate, 11 administration on a weekly schedule without vitamin supplementation resulted in dose-limiting stomatitis at only 30 mg/m 2 , so the biweekly schedule was subsequently pursued. However, significant clinical activity has been observed in patients with refractory T-cell lymphoma treated with pralatrexate on a weekly schedule with the addition of vitamins. 18 In addition, a phase I dose escalation trial of pralatrexate with vitamin supplementation is ongoing in patients with non-small cell lung cancer, including pharmacokinetics and measurements of vitamin concentrations, to determine whether these factors can predict the risk of toxicity. Based on preclinical data, 9 combinations with platinum agents may also be of interest. Nonetheless, with the dose and schedule used in this phase II study, pralatrexate showed a lack of response in mesothelioma and significant toxicity, even in patients who received folic acid and B 12 .
